Click to submit your search!

Prescribing Information | Important Safety Information | Our Advisory Board | For Health Care Professionals | Glossary

E-mail a Friend | | Print This Page

•  
• Rethink UC Remission
• Taking Lialda
• Living with UC
• Ulcerative Colitis Basics
• Connect 2 More Support Program

» Home » Our Advisory Board

Our Advisory Board

It’s hard to understand what it’s like to have ulcerative colitis (UC) unless you’ve been there yourself or gotten a close-up look through the eyes of someone you care about.

So we decided the only way to build a Web site for people with UC would be to ask for help from people with UC.

Our UC Advisory Board is a diverse group of individuals: men and women and students, parents, and professionals from different regions of the country. But they all have 2 things in common: they are all living with ulcerative colitis and they all want to help others learn from their experience. Their insights have shaped the content and the features of this Web site and other educational efforts by Shire, including our Connect 2 More program.

Find out how you can become a member of our Advisory Board.

Lialda is approved for the induction of remission in patients with active, mild to moderate ulcerative colitis. The safety and effectiveness of Lialda have been established in 2 eight-week clinical trials.

Important Safety Information

You should not take Lialda if you are allergic to salicylates (including mesalamine or aspirin) or to any of the ingredients of Lialda. Tell your doctor if you have a stomach blockage or are allergic to sulfasalazine. Mesalamine has been associated with a syndrome that may be difficult to distinguish from an ulcerative colitis flare-up. If you experience cramping, abdominal pain, bloody diarrhea, fever, headache or rash, talk to your doctor immediately. Some patients taking mesalamine have reported heart-related hypersensitivity reactions, such as inflammation of the heart muscle and inflammation of the lining of the heart. Tell your doctor if you have problems with your liver or kidneys.

In worldwide clinical trials, Lialda was generally well tolerated. The most common adverse events were headache and flatulence. As with other medications, some serious side effects may occur. Less than 1% of patients experienced inflammation of the pancreas, which led to discontinuation of therapy with Lialda.

Please see Lialda Full Prescribing Information

©2009 LIA-00772 09/09
Lialda^® is a registered trademark of Shire LLC. MMX^® is a registered trademark owned by Cosmo Technologies Ltd, Ireland, a wholly-owned subsidiary of Cosmo Pharmaceuticals SpA.
© 2009 Shire US Inc., Wayne, PA 19087 (800) 828-2088. All rights reserved.

This site is strictly intended for US residents and is governed solely by US laws and governmental regulations. Please see our online privacy policy for more information.

While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.